EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy
A post hoc analysis presented at EHA 2025 by Professor Martin Dreyling reinforces the clinical benefit of acalabrutinib in combination with bendamustine-rituximab for patients with high-risk mantle cell lymphoma and supports the combination as a promising first-line option for elderly patients with high-risk MCL.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen